Precision Medicine Portfolio Update: Illuccix China Phase 3 Study, TLX101-CDx and TLX250-CDx FDA Resubmissions

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today provides a precision medicine portfolio update in relation to: ...

ENHERTU® Plus Pertuzumab Approved in the U.S. as First New Treatment in More Than a Decade for First-Line Treatment of Patients with HER2 Positive Metastatic Br…

ENHERTU Plus Pertuzumab Approved in the U.S. for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer ...
Education NextOpinion

Are Teachers Abandoning Teaching?

For example, high-quality surveys from RAND find that teachers report higher levels of job-related stress and burnout than ...
Investing.com Canada

DBV stock soars after Viaskin Peanut meets primary endpoint in trial

Investing.com -- DBV Technologies stock surged 30% after the company announced positive results from its Phase III VITESSE clinical trial for VIASKIN Peanut, a treatment for peanut allergies in ...
Investing.com India

DBV Technologies stock soars after positive Phase 3 trial results

Investing.com -- DBV Technologies (NASDAQ:DBVT) stock soared 65.2% in after-hours trading Tuesday following the announcement of positive topline results from its Phase 3 VITESSE trial for the VIASKIN ...
eLife

Niche exclusion of a lung pathogen in mice with designed probiotic communities

This study reports a valuable method to predict the capacity of a candidate probiotic bacterium to metabolically outcompete a bacterial pathogen in the ecological niche of the murine respiratory tract ...
eLife

Subnational tailoring of ITN distributions to maximise malaria control

Insecticide-treated nets (ITNs) are the most impactful and cost-effective control tool against malaria. ITNs are primarily distributed through triennial mass campaigns across Africa, though overall ...